BSI-201
CAS No. 160003-66-7
BSI-201( Iniparib | NSC 746045 | IND-71677 | SAR240550 )
Catalog No. M12297 CAS No. 160003-66-7
BSI-201 (Iniparib;NSC 746045;IND-71677;SAR240550) is a potent, small molecule PARP1 inhibitor with strong anti-neoplastic effect.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 63 | In Stock |
|
| 25MG | 115 | In Stock |
|
| 50MG | 217 | In Stock |
|
| 100MG | 340 | In Stock |
|
| 200MG | 540 | In Stock |
|
| 500MG | 863 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBSI-201
-
NoteResearch use only, not for human use.
-
Brief DescriptionBSI-201 (Iniparib;NSC 746045;IND-71677;SAR240550) is a potent, small molecule PARP1 inhibitor with strong anti-neoplastic effect.
-
DescriptionBSI-201 (Iniparib;NSC 746045;IND-71677;SAR240550) is a potent, small molecule PARP1 inhibitor with strong anti-neoplastic effect, demonstrates the potential treatment of breast cancer.Breast Cancer Phase 2 Discontinued(In Vitro):Iniparib nonselectively modifies cysteine-containing proteins in tumor cells. Iniparib (100 μM) weakly inhibits SSB repair, and the inhibition can be reversed by knockdown of PARP1. Iniparib in combination with cisplatin is cytotoxic to Myc/MDA-231 with EMT changes.
-
In VitroIniparib nonselectively modifies cysteine-containing proteins in tumor cells. Iniparib (100 μM) weakly inhibits SSB repair, and the inhibition can be reversed by knockdown of PARP1. Iniparib in combination with cisplatin is cytotoxic to Myc/MDA-231 with EMT changes.
-
In Vivo——
-
SynonymsIniparib | NSC 746045 | IND-71677 | SAR240550
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP1
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number160003-66-7
-
Formula Weight292.0307
-
Molecular FormulaC7H5IN2O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(N)C1=CC=C(I)C([N+]([O-])=O)=C1
-
Chemical NameBenzamide, 4-iodo-3-nitro-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Liang H, et al. IDrugs. 2010 Sep;13(9):646-56.
2. O'Shaughnessy J, et al. N Engl J Med. 2011 Jan 20;364(3):205-14.
3. Fogelman DR, et al. Anticancer Res. 2011 Apr;31(4):1417-20.
molnova catalog
related products
-
UNBS-5162
UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
-
PARP1-IN-8?
PARP1-IN-8 is an effective inhibito of PARP1 (IC50 = 97 nM).
-
MK-4827 tosylate
A highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.
Cart
sales@molnova.com